

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA MEDICINE**

**華領醫藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(stock code: 2552)**

**CHANGE OF NON-EXECUTIVE DIRECTOR  
AND  
MEMBER OF THE REMUNERATION COMMITTEE**

The board of directors (the “**Board**”) of Hua Medicine (the “**Company**” together with its subsidiaries, the “**Group**”) announces the following changes of directors (“**Director (s)**”) of the Company:

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

Dr. Lian Yong CHEN (“**Dr. Chen**”) has tendered his resignation from the office of a non-executive Director and as a member of the Board’s remuneration committee (the “**Remuneration Committee**”) on March 16, 2022 with immediate effect. Dr. Chen resigned from his position in order to devote more time to his other work commitments and has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Dr. Chen for his valuable contributions during his tenure of office as a non-executive Director.

**CHANGE OF COMPOSITION OF REMUNERATION COMMITTEE**

Following Dr. Chen’s resignation, Mr. Junling Liu, an independent non-executive Director of the Company, will be appointed as a member of the Remuneration Committee with effect from March 16, 2022.

**APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board is delighted to announce that following Dr. Chen’s resignation, the Board appointed Ms. Wei ZHAO (趙瑋) (“**Ms. Zhao**”) as a non-executive Director with effect from March 16, 2022. The Board would like to welcome Ms. Zhao to the new appointment.

Ms. Zhao, aged 42, received her bachelor's degree of science with a major in business and finance in English from Shanghai Jiao Tong University in July 2001 and a master's degree of business administration from The University of Hong Kong in November 2013. Ms. Zhao is a non-practising member of the Chinese Institute of Certified Public Accountants. She is currently the executive director, Corporate Development and Investments of WuXi AppTec (Shanghai) Co., Ltd., and she is mainly responsible for sourcing, evaluating, executing and integrating its strategic acquisitions, investments and joint ventures. Since March 2019, she has also been serving as the non-executive Director of Clarity Medical Group Holding Limited, a company listed on the Stock Exchange (stock code: 1406) . Ms. Zhao worked at Ernst & Young Hua Ming Shanghai Branch (“**EY Shanghai**”) from September 2001 to April 2008. From February 2006 to April 2006, she briefly left EY Shanghai and worked for Deloitte & Touche Corporation Finance Ltd. Later, from May 2008 to November 2014, she worked at Ernst & Young (China) Advisory.

The term of Ms. Zhao's service as a non-executive Director is for three years commencing today and is subject to retirement and re-election at the annual general meeting of the Company pursuant to the articles of association of the Company. Ms. Zhao has entered into an appointment letter with the Company and upon the commencement of her appointment, she will be entitled to an annual director's fee of RMB450,000. The remuneration was determined by the Board with reference to her qualification, experience and the prevailing market rate.

As at the date of this announcement and save as disclosed above, Ms. Zhao confirms that she did not have any relationship with any director, senior management, chief executive or substantial shareholder or controlling shareholder of the Company and hold no other position within the Group. Within the meaning of Part XV of the Securities and Futures Ordinance, Ms. Zhao also confirms that she does not have any interest in the shares or underlying shares of the Company. She has confirmed that saved as disclosed above, she has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years and she does not have any major appointments and professional qualifications. There is no other matter that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to any of the requirements of rule 13.51 (2) of the Rules Governing the Listing of Securities on the Stock Exchange.

By Order of the Board

**Dr. Li Chen**

*Chief Executive Officer and Executive Director*

Hong Kong, March 16, 2022

*As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen, Dr. Lian Yong Chen and Ms. Wei Zhao as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.*

*On the date of this announcement, Dr. Lian Yong Chen resigned as a non-executive Director and Ms. Zhao Wei was appointed by the Board as a non-executive Director.*